- VC firm Vivo Capital outlays $740m for biotech investment Pharmaceutical Technology
- Vivo Capital secures $740M to invest in preclinical- and clinical-stage biotechs Fierce Biotech
- Vivo Capital Closes Opportunity Fund FIN News
- Vivo Capital closes on $740m for third cycle of evergreen public fund Venture Capital Journal
- Healthcare specialist Vivo Capital closes third Opportunity Fund cycle at $740m Alternatives Watch
The wire
More investor news
Hoxton Ventures backs human hair toothpaste pioneer in $4M round – Tech.eu
Next wave of VCs judging Startup Battlefield 200 contenders at TechCrunch Disrupt 2026 revealed – TechCrunch Venture
From Oatly to agritech: inside Sweden’s evolving foodtech ecosystem – Tech.eu
3 days left to exhibit: Get your brand in front of VCs and high-value leads at TechCrunch Disrupt 2026 – TechCrunch Venture
Zopa moves into AI voice banking services – Tech.eu
What should you wear to a tech interview? The essential dos and don’ts – Sifted